Bausch & Lomb

Bausch & Lomb was a subsidiary of Bausch Health Companies (formerly Valeant Pharmaceuticals) until May 2022, when it was fully separated via an initial public offering. Bausch Health retained a majority stake initially but the separation allowed Bausch & Lomb to operate as an independent company focused exclusively on eye health, with its own board and capital structure. The spinoff was part of a larger Bausch Health strategy to simplify its business into three distinct entities: Bausch & Lomb, Bausch Health's remaining pharma business, and a third aesthetic dermatology unit.

Brent Saunders, as CEO and Chairman, is the primary decision-maker for capital allocation, M&A, and R&D prioritization. Saunders has a track record as a dealmaker in ophthalmology from his tenure at Allergan and previously at Bausch & Lomb before it was sold to Valeant. The board of directors, which includes former Novartis CEO Joe Jimenez, provides oversight on major transactions. The firm does not operate a separate investment committee for portfolio management because it is an operating company that deploys capital internally rather than managing external funds.

No. Bausch & Lomb is a publicly traded operating company, not a family office or an investment fund. It does not make fund commitments, invest in external venture capital, or manage capital for third parties. Its deployment is entirely corporate — funding internal R&D, capital expenditures for manufacturing facilities, and acquiring complementary ophthalmic businesses that extend its product portfolio or geographic reach.

Bausch & Lomb does not acquire physician practices, unlike vertically integrated competitors that roll up ophthalmology and optometry clinics. Its model is product-focused: it sells devices, lenses, and pharmaceuticals to eye-care professionals rather than consolidating the provider market. This distinguishes it from firmss backed by private equity that attempt to control both the product distribution channel and the clinical end-user.

Bausch & Lomb relies on brand longevity, manufacturing scale in daily-disposable contact lenses, and consumer-to-prescription brand synergy. For example, it has leveraged its consumer-eye-drop brand Lumify to build relationships with eye-care professionals who can then recommend Bausch surgical products. The firm's 170-year history provides distribution relationships in over 100 countries that newer entrants lack. Its standalone structure allows faster decision-making on tuck-in acquisitions than competitors nested inside broader pharmaceutical conglomerates.

Bausch & Lomb's Waterford, Ireland plant is among the largest contact-lens manufacturing sites globally, producing the majority of its daily-disposable lenses. The Rochester, New York facility remains the center for surgical-device production and historical R&D. The dual footprint provides supply-chain redundancy and tax-efficient manufacturing, a structural consideration carried over from the Valeant era and maintained under the standalone entity.

Yes, though its trial scope is narrower than a large-cap pharma firm. Bausch & Lomb runs clinical trials primarily for new intraocular lenses, presbyopia-correcting drops, and surgical device approvals. Major recent programs include trials for the IC-8 small-aperture intraocular lens and supplemental filings for its enVista platform. Trial spending is a material operating cost line rather than a speculative R&D bet, given the regulatory pathways for medical devices are shorter than for systemic drugs.